JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth

Por Griner, Lori N., McGraw, Kathy L., Johnson, Joseph O., List, Alan F., Reuther, Gary W.
Publicado no Br J Haematol (2012)

Erythropoietin Receptor Signaling Is Membrane Raft Dependent

Por McGraw, Kathy L., Fuhler, Gwenny M., Johnson, Joseph O., Clark, Justine A., Caceres, Gisela C., Sokol, Lubomir, List, Alan F.
Publicado em 2012

HG-829 Is a Potent Noncompetitive Inhibitor of the ATP-Binding Cassette Multidrug Resistance Transporter ABCB1

Por Caceres, Gisela, Robey, Robert W., Sokol, Lubomir, McGraw, Kathy L., Clark, Justine, Lawrence, Nicholas J., Sebti, Said M., Wiese, Michael, List, Alan F.
Publicado no Cancer Res (2012)

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors

Por McGraw, Kathy L., Basiorka, Ashley A., Johnson, Joseph O., Clark, Justine, Caceres, Gisela, Padron, Eric, Heaton, Ruth, Ozawa, Yukiyasu, Wei, Sheng, Sokol, Lubomir, List, Alan F.
Publicado no PLoS One (2014)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

Por McGraw, Kathy L., Nguyen, Johnny, Komrokji, Rami S., Sallman, David, Al Ali, Najla H., Padron, Eric, Lancet, Jeffrey E., Moscinski, Lynn C., List, Alan F., Zhang, Ling
Publicado no Haematologica (2016)

Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41

Por Basiorka, Ashley A, McGraw, Kathy L, De Ceuninck, Leentje, Griner, Lori N, Zhang, Ling, Clark, Justine A, Caceres, Gisela, Sokol, Lubomir, Komrokji, Rami S, Reuther, Gary W, Wei, Sheng, Tavernier, Jan, List, Alan F
Publicado no Cancer Res (2016)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes

Por McGraw, Kathy L., Cluzeau, Thomas, Sallman, David A., Basiorka, Ashley A., Irvine, Brittany A., Zhang, Ling, Epling-Burnette, P.K., Rollison, Dana E., Mallo, Mar, Sokol, Lubomir, Solé, Francesc, Maciejewski, Jaroslaw, List, Alan F.
Publicado no Oncotarget (2015)

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

Por Sugimoto, Yuka, Sekeres, Mikkael A, Makishima, Hideki, Traina, Fabiola, Visconte, Valeria, Jankowska, Anna, Jerez, Andres, Szpurka, Hadrian, O'Keefe, Christine L, Guinta, Kathryn, Afable, Manuel, Tiu, Ramon, McGraw, Kathy L, List, Alan F, Maciejewski, Jaroslaw
Publicado em 2012

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide

Por Negoro, Eiju, Radivoyevitch, Tomas, Polprasert, Chantana, Adema, Vera, Hosono, Naoko, Makishima, Hideki, Przychodzen, Bartlomiej, Hirsch, Cassandra, Clemente, Michael J., Nazha, Aziz, Santini, Valeria, McGraw, Kathy L., List, Alan F., Sole, Francesc, Sekeres, Mikkael A., Maciejewski, Jaroslaw P.
Publicado no Leukemia (2016)

Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes

Por Sundaravel, Sriram, Duggan, Ryan, Bhagat, Tushar, Ebenezer, David L., Liu, Hui, Yu, Yiting, Bartenstein, Matthias, Unnikrishnan, Madhu, Karmakar, Subhradip, Liu, Ting-Chun, Torregroza, Ingrid, Quenon, Thomas, Anastasi, John, McGraw, Kathy L., Pellagatti, Andrea, Boultwood, Jacqueline, Yajnik, Vijay, Artz, Andrew, Le Beau, Michelle M., Steidl, Ulrich, List, Alan F., Evans, Todd, Verma, Amit, Wickrema, Amittha
Publicado no Proc Natl Acad Sci U S A (2015)

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

Por Basiorka, Ashley A., McGraw, Kathy L., Eksioglu, Erika A., Chen, Xianghong, Johnson, Joseph, Zhang, Ling, Zhang, Qing, Irvine, Brittany A., Cluzeau, Thomas, Sallman, David A., Padron, Eric, Komrokji, Rami, Sokol, Lubomir, Coll, Rebecca C., Robertson, Avril A. B., Cooper, Matthew A., Cleveland, John L., O’Neill, Luke A., Wei, Sheng, List, Alan F.
Publicado no Blood (2016)